We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
It has been well documented over the years that patients with pancreatic metastases from renal cell carcinoma have a better prognosis and overall survival, as evidenced by this case. A recent article supporting this is linked here: http://www.ncbi.nlm.nih.gov/pubmed/25872621.
Eric Wiedower
Jun 09, 2015
A recent article published by researchers at MD Anderson also supports the better prognosis/OS associated with pancreatic metastatsis from RCC. This study identified 228 patients in which 19% had pancreatic metastases. Median OS was 39 months (p=0.02) for patients with pancreatic metastases, compared to 26 months for patients without pancreatic metastases (p-value <0.01). Interestingly, the majority of patients in the cohort with pancreatic metastases had multiple (3 or more) organ sites with metastatic disease, but have much better survival as compared to those without pancreatic metsastases. Article can be found at PMID: 26032863 .
Mayer Gorbaty
Jun 20, 2015
Interesting observation. Are there any theories of why pancreatic mets do better than non-pancreatic mets?
Nov 16, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Bradley G. Somer MD
May 05, 2015
Eric Wiedower
Jun 09, 2015
Mayer Gorbaty
Jun 20, 2015
Nov 16, 2024
Pending Moderator approval.